Cassiopeia study multiple myeloma
Web31 Mar 2024 · Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes … Web28 Sep 2024 · As reported in The Lancet Oncology by Philippe Moreau, MD, and colleagues, an interim analysis of part 2 of the phase III CASSIOPEIA trial has shown …
Cassiopeia study multiple myeloma
Did you know?
WebHigh-risk cytogenetic abnormalities and International Staging System (ISS) disease stage III confer poor outcomes in MM pts. In the phase 3 CASSIOPEIA study, at median follow … WebAims To investigate the incidence of PNP in patients treated in the Cassiopeia trial, to evaluate the role of CD38 antibody (daratumumab) treatment in development of PNP, and to identify risk factors for the development of PNP. Methods
Web11 Dec 2024 · For patients in the D-VTd arm who received daratumumab maintenance, the rates of MRD-negativity were 64.2% vs 57.6% with observation (OR, 1.43; P = .1037). … Web3 Jun 2024 · Minimal residual disease (MRD) by multiparameter flow cytometry (MFC) is the most effective tool to define a deep response in multiple myeloma (MM). We conducted …
Web5 Jun 2024 · In the phase 3 DETERMINATION trial, patients with newly diagnosed multiple myeloma were randomly assigned to treatment with lenalidomide, bortezomib, and dexamethasone with and without an autologous stem cell transplant (ASCT). All patients received lenalidomide maintenance until progression. Web22 Jun 2024 · Voluntary written informed consent must be given before performance of any study-related procedure not part of normal medical care, with the understanding that the …
WebTreatment protocols for multiple myeloma are provided below. In addition to global treatment recommendations, treatment recommendations for the tracking are included: Primary therapy (induction for stem cell transplantation) Care with lapse after graft Diseased anybody are not transplant candidates General treating recommendations...
Web21 Oct 2024 · Multiple myeloma is an incurable blood cancer that starts in the bone marrow and is characterized by an excess proliferation of plasma cells. 1 Multiple myeloma is … hyundai california sandWeb13 Sep 2024 · CASSIOPEIA is a two-part, open-label, randomised, phase 3 trial of patients aged 18–65 years with newly diagnosed multiple myeloma and Eastern Cooperative … hyundai california testingWebDaratumumab and Standard Therapy for Myeloma 01:53. The risk of multiple myeloma increases with age, 1-3 and despite progress in the development of effective treatment, … molly cantorWeb11 Apr 2024 · Background aims Adoptive cell therapy with chimeric antigen receptor (CAR)-expressing natural killer (NK) cells is an emerging approach that holds promise in multiple myeloma (MM). However, the generation of CAR-NK cells targeting CD38 is met with obstacles due to the expression of CD38 on NK cells. molly caplanWeb23 Oct 2024 · Copenhagen, Denmark; October 21, 2024 – Genmab A/S (Nasdaq: GMAB) announced today positive topline results from the second part of the Phase 3 … molly capron mdWeb21 Oct 2024 · Second part of the Phase 3 CASSIOPEIA study of daratumumab as maintenance treatment for patients with newly diagnosed multiple myeloma eligible for … hyundai california headquartersWeb19 Jul 2024 · Based on data from part 1 of the phase III CASSIOPEIA trial, in September 2024, the FDA granted approval to daratumumab in combination with bortezomib, thalidomide, and dexamethasone (D-VTd) for adults with newly diagnosed multiple myeloma who are eligible for ASCT. 6,7 An interim analysis from part 2 of the trial … hyundai california maryland